Microfluidic Aerosolization of Lipid Nanoparticles Without Shear Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing inhalation-based mRNA delivery methods, particularly using nebulizers, face challenges such as shearing forces that destabilize nanoparticles, leading to reduced mRNA encapsulation efficiency and integrity, which compromises the effectiveness and safety of pulmonary delivery.
Innovation Solution
A microfluidic aerosolization platform that generates aerosols using a CMOS-based chip with individually addressable nozzles, minimizing shearing forces and preserving nanoparticle integrity by controlling droplet size and frequency, ensuring precise and efficient delivery of mRNA encapsulated within lipid nanoparticles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional nebulizers are used for aerosolization, then aerosol generation is achieved, but shear-induced damage occurs to lipid nanoparticles reducing mRNA encapsulation and delivery efficiency
Solution Approach 1:
The patent replaces conventional mechanical aerosolization systems (nebulizers that generate high shear forces) with a microfluidic system that uses controlled fluid flow through microchannels. This substitution eliminates the harmful shear forces while maintaining aerosol generation capability, thereby preserving nanoparticle integrity and mRNA delivery efficiency
Solution Approach 2:
The patent changes the physical parameters of the aerosolization process by using microfluidic channels with precisely controlled dimensions and flow rates. This allows generation of aerosols with optimized droplet sizes and controlled shear forces, achieving both nanoparticle preservation and effective delivery
2Reliability
If microfluidic aerosolization is used to minimize shear forces, then nanoparticle integrity is preserved, but device complexity increases
Solution Approach 1:
The patent divides the microfluidic system into modular components including separate reservoirs for lipid nanoparticle and buffer solutions, individual microfluidic chambers for aerosol generation, and distinct delivery pathways. This segmentation allows for easier manufacturing, assembly, and maintenance while preserving nanoparticle integrity
Solution Approach 2:
The microfluidic device is designed with multi-functional capabilities, serving as both a mixing chamber for lipid nanoparticle preparation and an aerosolization system. This integration reduces the number of separate components needed, thereby reducing overall device complexity while maintaining nanoparticle integrity
3Manufacturing precision
If individually addressable microfluidic chambers are used for precise droplet control, then droplet size and frequency are precisely controlled, but manufacturing precision requirements increase
Solution Approach 1:
The patent optimizes the physical and chemical parameters of the microfluidic chambers, including channel dimensions, heater power levels, and flow rates, to achieve precise droplet control. By carefully selecting and controlling these parameters, the system achieves consistent droplet size and frequency while maintaining manufacturability through standard fabrication processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microfluidic platform maintains nanoparticle integrity and mRNA encapsulation, achieving higher delivery efficiency to lung tissues with reduced immunogenicity and systemic exposure, facilitating effective pulmonary gene therapy.
Implementation Method 1
heat sources in the form of resistors in thermal communication with each of the microfluidic chambers
Data Source
AI summary
Leveraging the extensive surface area of the lungs for gene therapy, inhalation route offers distinct advantages for delivery. Clinical nebulizers that employ vibrating mesh technology are the standard choice for converting liquid medicines into aerosols. However, they have limitations when it comes to delivering mRNA through inhalation, including severe damage to nanoparticles due to shearing forces. A microfluidic aerosolization platform (MAP) can preserves the structural and physicochemical integrity of lipid nanoparticles, enabling safe and efficient mRNA delivery to the respiratory system. Results demonstrated the superiority of the novel microfluidic aerosolizer over the conventional vibrating mesh nebulizer, as it avoided problems such as particle aggregation, loss of mRNA encapsulation, and deformation of nanoparticle morphology. Notably, aerosolized nanoparticles generated by the microfluidic aerosolization platform led to enhanced transfection efficiency across various cell lines. In vivo experiments with mice that inhaled these aerosolized nanoparticles revealed successful, lung-specific mRNA transfection without observable signs of toxicity. This pioneering MAP represents a significant advancement for the pulmonary gene therapy, enabling precise and effective delivery of aerosolized nanoparticles.